论文部分内容阅读
本文应用双抗体夹心直接ELISA法对36例胃癌患者血清SIL－2R水平进行了测定。胃癌患者血清SIL2R水平明显高于正常人群（p＜0．01）及慢性良性胃病患者（p＜0．01）；Ⅲ～Ⅳ期患者血清SIL-2R水平明显高于Ⅰ～Ⅱ期患者（p＜0．01）；胃癌根治术后10天血清SIL-2R水平较术前明显下降（p＜0．01），与正常人群对照无明显差异（p＞0．05）。结果说明血清SIL-2R测定可作为胃癌的诊断、疗效观察和预后评价的一项有价值的指标。
The serum SIL-2R levels in 36 patients with gastric cancer were measured by double antibody sandwich direct ELISA. Serum SIL2R levels in gastric cancer patients were significantly higher than those in the normal population (p<0.01) and chronic benign gastropathy patients (p<0.01). Serum SIL-2R levels in patients with stage III to IV were significantly higher than those in stage I to II patients (p <0.01); Serum SIL-2R levels decreased significantly after surgery 10 days after radical gastrectomy (p <0.01), and no significant difference (p> 0.05). The results show that serum SIL-2R can be used as a valuable indicator for the diagnosis, efficacy observation and prognosis evaluation of gastric cancer.